User:Mr. Ibrahem/Polatuzumab vedotin

Polatuzumab vedotin, sold under the brand name Polivy, is a medication used to treat diffuse large B-cell lymphoma in combination with bendamustine and rituximab. It is used when other treatments have not worked. It is given by gradual injection into a vein.

Common side effects include low red blood cells, low platelets, low white blood cells, diarrhea, nausea, and fever. Other side effects may include peripheral neuropathy, infusion reaction, tumor lysis syndrome, liver problems, and infection. Use in pregnancy may harm the baby. It is a monoclonal antibody joined with monomethyl auristatin E (MMAE) that attaches to CD79b.

Polatuzumab vedotin was approved for medical use in the United States in 2019 and Europe in 2020. In the United Kingdom 140 mg costs the NHS about £11,000 as of 2021. This amount in the United States costs about 15,700 USD.